Brief: Enlivex Receives Regulatory Authorization To Expand Its Phase IIb Trial Evaluating Allocetra In Severe And Critical COVID-19 Patients Into Greece
13/12/2021 13:19
Dec 13 (Reuters) - Enlivex Therapeutics Ltd ENLV.TA :
* ENLIVEX RECEIVES REGULATORY AUTHORIZATION TO EXPAND ITS
PHASE
IIB TRIAL EVALUATING ALLOCETRA IN SEVERE AND CRITICAL COVID-19
PATIENTS INTO GREECE
* ENLIVEX THERAPEUTICS LTD - CURRENTLY EXPECTS THAT TOP-LINE
DATA
FROM TRIAL WILL BE AVAILABLE IN LATE 2022 OR Q1 OF 2023
Source text for Eikon: ID:nGNXcgdqP9
Further company coverage: ENLV.TA
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Enlivex
See all newsBrief: Enlivex Ltd Registers Up To 23,333,333 Ordinary Shares For Resale By Selling Shareholder
Brief: Enlivex Announces Second Regulatory Approval For Phase 2B Trial Of Allocetra In Age-Related Primary Moderate-To-Severe Knee Osteoarthritis
Brief: Enlivex Therapeutics Files For Offering Of Up To $299.6 Mln Of Ordinary Shares
Brief: Enlivex Announces Positive 6-Month Topline Data For Patients with Knee Osteoarthritis
Brief: Enlivex Files Patent for Allocetra Use in Osteoarthritis Treatment